Waltham, MA
Phase Forward announced a multi-year agreement with Gedeon Richter Plc., a leading pharmaceutical company in Central-Eastern Europe. Gedeon Richter plans to adopt Phase Forward’s Clintrial™ product for its clinical trial data management activities.
Founded in 1901 and headquartered in Budapest, Hungary, Gedeon Richter’s organization manufactures and markets generic pharmaceutical products for the treatment of a variety of therapy areas including gynecology and cardiology. After completing a competitive product review, Gedeon Richter selected Phase Forward.
“We know that we are collaborating with the premier technology provider for clinical trials – and we look forward to garnering the benefits inherent in greater drug trial efficiencies,” said György Németh, medical director, Gedeon Richter.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.